Oligodendroglial neoplasms: Current concepts, misconceptions, and folklore

Advances in Anatomic Pathology

Volumn 8, Issue 4, 2001, Pages 183-199

  Perry, Arie ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glioma; Oligoastrocytoma; Oligodendroglioma; Prognosis; Tumor genetics

Indexed keywords

TUMOR MARKER;

BRAIN TUMOR; CANCER STEM CELL; DIFFERENTIAL DIAGNOSIS; ELECTRON MICROSCOPY; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PATHOLOGY; PROGNOSIS; REVIEW;

BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, ELECTRON; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELLS;

EID: 0035403224     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-200107000-00001     Document Type: Review

References (118)

1. Bailey P, Bucy PC. Oligodendrogliomas of the brain. J Pathol Bacteriol 1929;32:735-51.
2. Sarkar C, Subimal R, Tandon PN. Oligodendroglial tumors. An immunohistochemical and electron microscopic study. Cancer 1988;61:1862-6.
3. Schwechheimer K, Gass P, Berlet HH. Expression of oligodendroglia and Schwann cell markers in human nervous system tumors. An immunomorphological study and Western blot analysis. Acta Neuropathol 1992;83:283-91.
4. Min KW, Scheithauer BW. Oligodendroglioma: the ultrastructural spectrum. Ultrastruct Pathol 1994;18:47-60. (Pubitemid 24131612)
5. Sung CC, Collins R, Li J, et al. Glycolipids and myelin proteins in human oligodendrogliomas. Glycoconjugate J 1996;13:433-43. (Pubitemid 26179976)
6. Shoshan Y, Nishiyama A, Chang A, et al. Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci USA 1999;96:10361-6. (Pubitemid 29422563)
7. Raff MC, Miller RH, Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 1983;303:390-6. (Pubitemid 13094875)
8. Noble M, Gutowski N, Bevan K, et al. From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte-type-2 astrocyte lineage. Glia 1995;15:222-30.
9. Ng H-K, Ko HC, Tse CCH. Immunohistochemical and ultrastructural studies of oligodendrogliomas revealed features of neuronal differentiation. Int J Surg Pathol 1994;2:47-56. (Pubitemid 2125859)
10. Giangaspero F, Cenacchi G, Losi L, et al. Extraventricular neoplasms with neurocytoma features. Am J Surg Pathol 1997;21:206-12.
11. Burger PC, Rawlings CE, Cox EB, et al. Clinicopathologic correlations in the oligodendroglioma. Cancer 1987;59:1345-52. (Pubitemid 17035482)
12. Bruner JM. Oligodendroglioma: diagnosis and prognosis. Sem Diag Pathol 1987;4:251-61.
13. Shaw EG, Scheithauer BW, O'Fallon JR, et al. Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992;76:428-34.
14. Celli P, Nofrone I, Palma L, et al. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994;35:1018-34.
15. Daumas-Duport C, Varlet P, Tucker M-L, et al. Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neuro-Oncol 1997;34:37-59. (Pubitemid 27270251)
16. Donahue B, Scott CB, Nelson JS, et al. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of radiation therapy oncology group 83-02. Int J Radiat Oncol Biol Phys 1997;38:911-4. (Pubitemid 27353668)
17. Bigner SH, Rasheed BKA, Wiltshire R, et al. Morphologic and molecular genetic aspects of oligodendroglial neoplasms. NeuroOncology 1999;1:52-60.
18. Fortin D, Cairncross GJ, Hammond RR. Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 1999;45:1279-91.
19. Levin VA. Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading. Neuro-Oncology 1999;1:69-80.
20. Perry JR, Louis DN, Cairncross JG. Current treatment of oligodendrogliomas. Arch Neurol 1999;56:434-6. (Pubitemid 29166336)
21. Reifenberger G, Kros JM, Burger PC, et al. Oligodendroglioma. In: Kleihues P, Cavenee WK, eds. World Health Organization classification of tumours. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press, 2000:55-70.
22. Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Frontiers Biosci 2000;5:d213-d231.
23. Coons SW, Johnson PC, Scheithauer BW, et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997;79:1381-93. (Pubitemid 27143246)
24. Jagadha V, Halliday WC, Becker LE. Glial fibrillary acidic protein (GFAP) in oligodendrogliomas: a reflection of transient GFAP expression by immature oligodendroglia. Can J Neurol Sci 1986;13:307-11. (Pubitemid 17219249)
25. Kros JM, van Eden CG, Stefanko SZ, et al. Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas. Cancer 1990;66:1204-12. (Pubitemid 20310662)
26. Kros JM, de Jong AAW, van der Kwast TH. Ultrastructural characterization of transitional cells in oligodendrogliomas. J Neuropathol Exp Neurol 1992;51:186-93.
27. Takei Y, Mirra SS, Miles ML. Eosinophilic granular cells in oligodendrogliomas. An ultrastructural study. Cancer 1976;1968-76.
28. Kros JM, van den Brink WA, van Loon-van Luyt JJM, et al. Signet-ring cell oligodendroglioma- report of two cases and discussion of the differential diagnosis. Acta Neuropathol 1997;93:638-43. (Pubitemid 27239255)
29. Smith MT, Ludwig CL, Godfrey AD, et al. Grading of oligodendrogliomas. Cancer 1983;52:2107-14. (Pubitemid 14232255)
30. Mork SJ, Halvorsen TB, Lindegaard K-F, et al. Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol 1986;45:65-78. (Pubitemid 16189844)
31. Daumas-Duport C, Tucker M-L, Kolles H, et al. Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neuro-Oncol 1997;34:61-78. (Pubitemid 27270252)
32. Giannini C, Sheithauer BW, Weaver AL, et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 2001;60:248-62. (Pubitemid 32209644)
33. Heegaard S, Sommer HM, Broholm H, et al. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 1995;76:1809-13.
34. Coons SW, Johnson PC, Pearl DK. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 1997;41:878-85. (Pubitemid 27422116)
35. Cairncross JG, Ueki K, Zlatescu C, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Nat Cancer Inst 1998;90;1473-9. (Pubitemid 28482012)
36. Schiffer D, Bosone I, Dutto A, et al. The prognostic role of vessel productive changes and vessel density in oligodendroglioma. J Neuro-Oncol 1999;44:99-107.
37. Shaw EG, Scheithauer BW, O'Fallon JR, et al. Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 1994;34:577-82. (Pubitemid 24100523)
38. Bruner JM, Inouye L, Fuller GN, et al. Diagnostic discrepancies and their clinical impact in a neuropathology referral practice. Cancer 1997;79:796-803. (Pubitemid 27076346)
39. Rorke LB. Pathologic diagnosis as the gold standard (editorial). Cancer 1997;665-7. (Pubitemid 27076330)
40. Krouwer HGJ, van Duinen SG, Kamphorst W, et al. Oligoastrocytomas: a clinicopathological study of 52 cases. J Neuro-Oncol 1997;33:223-38. (Pubitemid 27241311)
41. Perry A, Anderl KA, Borell TJ, et al. Detection of p16, RB, CDK4, and p53 gene deletion / amplification by fluorescence in situ hybridization (FISH) in 96 gliomas. Am J Clin Pathol 1999;112:801-9. (Pubitemid 30212511)
42. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144-52. (Pubitemid 29363922)
43. Aldape K, Simmons ML, Davis RL, et al. Discrepancies in diagnoses of neuroepithelial neoplasms. The San Francisco Bay Area adult glioma study. Cancer 2000;88:2342-9. (Pubitemid 30247135)
44. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56:1098-104. (Pubitemid 27430471)
45. Jeuken JWM, Sprenger SHE, Wesseling P, et al. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol 1999;58:606-12. (Pubitemid 29264940)
46. Motoi M, Yoshino T, Hayashi K, et al. Immunohistochemical studies on human brain tumors using antiLeu7 monoclonal antibody in paraffin-embedded specimens. Acta Neuropathol 1985;66:75-7. (Pubitemid 15138013)
47. Daumas-Duport C, Scheithauer BW, Chodkiewicz J-P, et al. Dysembryoplastic neuroepithelial tumor: a surgically curable tumor of young patients with intractable partial seizures. Report of thirty-nine cases. Neurosurgery 1988;23:545-56. (Pubitemid 18268160)
48. Daumas-Duport C. Dysembryoplastic neuroepithelial tumors. Brain Pathol 1993;3:283-95.
49. Daumas-Duport C, Varlet P, Bacha S, et al. Dysembryoplastic neuroepithelial tumors: nonspecific histological forms - A study of 40 cases. J Neuro-Oncol 1999;41:267-80. (Pubitemid 29209815)
50. Honavar M, Janota I, Polkey CE. Histological heterogeneity of dysembryoplastic neuroepithelial tumor: identification and differential diagnosis in a series of 74 cases. Histopathology 1999;34:342-56. (Pubitemid 29229989)
51. Cervera-Pierot P, Varlet P, Chodkiewicz J-P, et al. Dysembryoplastic neuroepithelial tumors located in the caudate nucleus area: report of four cases. Neurosurgery 1997;40:1065-70. (Pubitemid 27202692)
52. Fujimoto K, Ohnishi H, Tsujimoto M, et al. Dysembryoplastic neuroepithelial tumor of the cerebellum and brainstem. J Neurosurg 2000;93:487-9.
53. Hirose T, Scheithauer BW, Lopes MBS, et al. Dysembryoplastic neuroepithelial tumor (DNT): an immunohistochemical and ultrastructural study. J Neuropathol Exp Neurol 1994;53:184-95. (Pubitemid 24081891)
54. Hassoun J, Gambarelli D, Grisoli F, et al. Central neurocytoma. An electron microscopic study of two cases. Acta Neuropathol 1982;56:151-6. (Pubitemid 12179875)
55. Hassoun J, Soylemezoglu F, Gambarelli D, et al. Central neurocytoma: a synopsis of clinical and histological features. Brain Pathol 1993;3:297-306. (Pubitemid 23276696)
56. Figarella-Branger D, Pellissier JF, Daumas-Duport C, et al. Central neurocytomas. Critical evaluation of a small-cell neuronal tumor. Am J Surg Pathol 1992;16:97-109.
57. Schild SE, Scheithauer BW, Haddock MG, et al. Central neurocytomas. Cancer 1997;79:790-5. (Pubitemid 27076345)
58. Min KW, Scheithauer BW. Clear cell ependymoma: a mimic of oligodendroglioma: clinicopathologic and ultrastructural considerations. Am J Surg Pathol 1997;21:820-6. (Pubitemid 27406552)
59. Chan AS, Leung Sy, Wong MP, et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytomas, oligodendroglioma, and ependymoma. Am J Surg Pathol 1998;22:816-26.
60. Varlet P, Guillamo JS, Nataf F, et al. Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival. Neuropathol Appl Neurobiol 2000;26:379-89. (Pubitemid 30609434)
61. Schiffer D, Dutto A, Cavalla P, et al. Prognostic factors in oligodendroglioma. Can J Neurol Sci 1997;24:313-9. (Pubitemid 28064758)
62. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 1987;59:1617-25. (Pubitemid 17060106)
63. Perry A, Jenkins RB, O'Fallon JR, et al. Clinicopathologic study of similarly treated anaplastic astrocytic tumors: an analysis of DNA content (ploidy), cellular proliferation, and p53 expression. Cancer 1999;86:672-83. (Pubitemid 29379414)
64. Shafqat S, Hedley-Whyte T, Henson JW. Age-dependent rate of anaplastic transformation in low-grade astrocytoma. Neurology 1999;52:867-9. (Pubitemid 29120202)
65. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncology 1999;1:44-51.
66. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms: a retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993;78:767-75. (Pubitemid 23121919)
67. Berger MS, Deliganis AV, Dobbins J, et al. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1994;74:1784-91. (Pubitemid 24301834)
68. Scerrati M, Roselli R, Lacoangeli M, et al. Prognostic factors in low grade (WHO grade II) gliomas of the cerebral hemispheres; the role of surgery. J Neurol Neurosurg Psychiatry 1996;61:291-6. (Pubitemid 26293725)
69. Rostomily RC, Keles GE, Berger MS. Radical surgery in the management of low-grade and high-grade gliomas. Baillieres Clin Neurol 1996;5:345-69.
70. Glass J, Hochberg FH, Gruber ML, et al. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 1992;76:741-5.
71. Kyritsis AP, Yung WK, Bruner J, et al. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 1993;32:365-71. (Pubitemid 23082097)
72. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994;12:2013-21. (Pubitemid 24356016)
73. Kim L, Hochberg FH, Thornton AF, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 1996;85:602-7. (Pubitemid 26315193)
74. Soffietti R, Ruda R, Bradac GB, et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998;43:1066-73. (Pubitemid 28481106)
75. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000;48:825-30.
76. Cairncross JG, Louis DL. Molecular diagnosis of anaplastic oligodendroglioma subtypes [abstract]. Neuro-Oncology 2000;2:254.
77. Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 1994;30:567-73. (Pubitemid 24304467)
78. Kros JM, van Eden CG, Vissers CJ, et al. Prognostic relevance of DNA flow cytometry in oligodendroglioma. Cancer 1992;69:1791-8.
79. Coons SW, Johnson PC, Pearl DK, et al. Prognostic significance of flow cytometry deoxyribonucleic acid analysis of human oligodendrogliomas. Neurosurgery 1994;34:680-7. (Pubitemid 24100538)
80. Rey JA, Bello MJ, de Campos JM, et al. Chromosomal patterns in human malignant astrocytomas. Cancer Genet Cytogenet 1987;29:201-21. (Pubitemid 18002148)
81. Rey JA, Bello MJ, de Campos JM, et al. Chromosomal composition of a series of 22 human low-grade gliomas. Cancer Genet Cytogenet 1987;29:223-37. (Pubitemid 18002149)
82. Bigner SH, Mark J, Burger PC, et al. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res 1988;88:405-11. (Pubitemid 18045778)
83. Jenkins RB, Kimmel DW, Moertel CA, et al. A cytogenetic study of 53 human gliomas. Cancer Genet Cytogenet 1989;39:253-79. (Pubitemid 19214168)
84. Bigner SH, Mark J, Bigner DD. Cytogenetics of human brain tumors. Cancer Genet Cytogenet 1990;47:141-54. (Pubitemid 20226620)
85. Griffin CA, Long PP, Carson BS, et al. Chromosome abnormalities in low-grade central nervous system tumors. Cancer Genet Cytogenet 1992;60:67-73.
86. Thiel G, Losanowa T, Kintzel D, et al. Karyotypes in 90 human gliomas. Cancer Genet Cytogenet 1992;58:109-20.
87. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 1992;84-90.
88. Diedrich U, Lucius J, Baron E, et al. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol 1995;242:683-8.
89. Sauter G, Maeda T, Waldman FM, et al. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol 1996;148:1047-53. (Pubitemid 26108242)
90. Perry A, Tonk V, McIntire D, et al. Interphase cytogenetic (in situ hybridization) analysis of astrocytomas using archival formalin-fixed, paraffin-embedded tissue and light microscopy, Am J Clin Pathol 1997;108:166-74. (Pubitemid 27328289)
91. Etienne M-C, Formento J-L, Lebrun-Frenay C, et al. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 1998;4:2383-90. (Pubitemid 28477903)
92. Leenstra S, Oskam NT, Bijleveld EH, et al. Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer 1998;79:159-65. (Pubitemid 28201688)
93. Lin H, Bondy ML, Langford LA, et al. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res 1998;4:2447-54. (Pubitemid 28477911)
94. Balesaria S, Brock C, Bower M, et al. Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas. Br J Cancer 1999;81;1371-7.
95. Muller M, Schmidt MC, Schmidt O, et al. Molecular genetic analysis as a tool for evaluating stereotactic biopsies of glioma specimens. J Neuropathol Exp Neurol 1999;58:40-5. (Pubitemid 29053024)
96. Raffel C, Frederick L, O'Fallon JR, et al. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 1999;5:4085-90. (Pubitemid 30013789)
97. Sano T, Lin H, Chen X, et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 1999;59:1820-4. (Pubitemid 29186149)
98. von Deimling A, Fimmers R, Schmidt MC, et al. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 2000;59:544-58. (Pubitemid 30368314)
99. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-90. (Pubitemid 24345665)
100. Bello MJ, Leone PE, Vaquero J, et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995;64;207-10.
101. Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;54:91-5.
102. Bigner SH, Matthews MR, Rasheed BKA, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999;155:375-86. (Pubitemid 29370388)
103. Ritland SR, Ganju V, Jenkins RB. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosom Cancer 1995;12:277-82.
104. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-45. (Pubitemid 30078545)
105. Ino Y, Zlatescu MC, Sasaki H, et al. Long survival and therapeutic responses in patients with histologically disparate highgrade gliomas demonstrating chromosome 1p loss. J Neurosurg 2000;92:983-90. (Pubitemid 30346517)
106. Mai M, Huang H, Reed C, et al. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics 1998;51:359-63. (Pubitemid 28413202)
107. INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas. Brain Pathol 1999;9:639-43.
108. Husemann K, Wolter M, Buschges R, et al. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 1999;58:1041-50. (Pubitemid 29468265)
109. Bello MJ, de Campos JM, Vaquero J, et al. hRAD54 gene and 1p high-resolution deletion mapping analyses in oligodendrogliomas. Cancer Genet Cytogenet 2000;116:142-7.
110. von Deimling A, Louis DN, von Ammon K, et al. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992;52:4277-9.
111. von Deimling A, Bender B, Jahnke R, et al. Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q. Cancer Res 1994;54:1397-1401. (Pubitemid 24106394)
112. von Deimling A, Nagel J, Bender B, et al. Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 1994;57:676-80. (Pubitemid 24201358)
113. Yong WH, Chou D, Ueki K, et al. Chromosome 19q deletions in human gliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112. J Neuropathol Exp Neurol 1995;54:622-6.
114. Yong WH, Ueki K, Chou D, et al. Cloning of a highly conserved human protein serine-threonine phosphatase gene from the glioma candidate region on chromosome 19q13.3. Genomics 1995;29:533-6.
115. Smith JS, Tachibana I, Pohl U, et al. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics 2000;64:44-50. (Pubitemid 30165073)
116. Nakamura M, Yang F, Fujisawa H, et al. Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 2000;59:539-43. (Pubitemid 30368313)
117. Caskey LS, Fuller GN, Bruner JM, et al. Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling. Histol Histopathol 2000;15:971-81. (Pubitemid 30488576)
118. Watson MA, Perry A, Budhjara V, et al. Gene expression profiling with oligonucleotide microarrays distinguishes WHO grade of oligodendrogliomas. Cancer Res 2001;61:1825-9. (Pubitemid 32691992)